Chemerin, A Novel Therapeutic Target For Modulation Of Adipose Tissue Mass
Funder
National Health and Medical Research Council
Funding Amount
$535,621.00
Summary
Obesity is a significant public health issue due to its increasing prevalence and association with other diseases including cardiovascular disease. Efforts to pharmacologically prevent and treat obesity are impaired by an incomplete understanding of the genes and metabolic processes involved. This project will use cell and animal models to examine the processes that occur during the expansion of fat tissue which will broaden our understanding of obesity and assist in identifying new therapies.
Novel Gp130 Receptor Ligands To Treat Metabolic Disease
Funder
National Health and Medical Research Council
Funding Amount
$708,267.00
Summary
Over the past decade work from our group has identified that a group of cytokines termed the gp130 receptor cytokines can lead to weight loss in animals and humans. Unfortunately, due to side effects, clinical trials using peptides analogues of these cytokines have failed. We believe that we know why this has occurred and we think we have developed new peptides that will alleviate these side effects. This application will test the efficacy of these novel peptides in mammals in vivo.
Ciliary Neurotrophic Factor: A Novel Theraputic Agent For The Prevention Of Muscle Insulin Resistance
Funder
National Health and Medical Research Council
Funding Amount
$602,673.00
Summary
In 1995 leptin was discovered and scientists world-wide hoped that this was the great panacea in the treatment of obesity related disorders. Alas, from 1995-1997 the identification of a novel cytokine inducible compound termed suppressor of cytokine signaling (SOCS) that negatively regulated leptin signalling and lead to leptin resistance, quashing hopes for a viable anti-obesogenic drug. Recently, however, work from our group has demonstrated that the neuropoietic cytokine, ciliary neurotrophic ....In 1995 leptin was discovered and scientists world-wide hoped that this was the great panacea in the treatment of obesity related disorders. Alas, from 1995-1997 the identification of a novel cytokine inducible compound termed suppressor of cytokine signaling (SOCS) that negatively regulated leptin signalling and lead to leptin resistance, quashing hopes for a viable anti-obesogenic drug. Recently, however, work from our group has demonstrated that the neuropoietic cytokine, ciliary neurotrophic factor (CNTF), can act in an anti-obesogenic fashion in a manner similar to leptin. However, unlike leptin, when we place rodents on a high fat diet, the effects of CNTF persist and override induction SOCS proteins. This project will examine the biochemical pathways that allow the actions of CNTF to persist in the presence of diet-induced obesity. This is of major significance because in completing this work, the potential for the development of peripheral tissue drug targets for the treatment of obesity related diseases are both tangible and realistic.Read moreRead less